Atrial fibrillation imposes a substantial economic burden in the United States, with estimated national incremental costs ranging from $6.0 to $26.0 billion.
On the basis of current US age- and sex-specific prevalence data, the national incremental AF cost is estimated to range from 6. 0 to 26. 0 billion.
Kim et al. (2011) studied this question.